Sharma P K, Yadav T P, Gautam R K, Taneja N, Satyanarayana L
Department of Dermatology, Dr Ram Manohar Lohia Hospital, New Delhi, India.
J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):241-4. doi: 10.1016/S0190-9622(00)90132-4.
The study stemmed from an incidental observation of improvement in 2 patients with pityriasis rosea while receiving erythromycin.
The purpose of the study was to evaluate the efficacy of erythromycin in patients with pityriasis rosea.
A double-blind, placebo-controlled clinical study was performed in an outpatient setting in a major hospital. Ninety patients over a period of 2 years were alternatively assigned to treatment group or placebo group. Patients in the treatment group received erythromycin in divided doses for 14 days. The response was categorized as complete response, partial response, or no response. All patients were followed up for 6 weeks.
Both groups were comparable with regard to age at presentation, sex, and average duration of disease at the time of reporting to the clinic. Upper respiratory tract infection before the appearance of skin lesions was reported in 68.8% of all patients. Complete response was observed in 33 patients (73.33%) in the treatment group and none in the placebo group (P <.0001).
Oral erythromycin was effective in treating patients with pityriasis rosea.
该研究源于对2例玫瑰糠疹患者在接受红霉素治疗时病情改善的偶然观察。
本研究的目的是评估红霉素对玫瑰糠疹患者的疗效。
在一家大型医院的门诊进行了一项双盲、安慰剂对照的临床研究。在2年的时间里，90例患者被交替分配到治疗组或安慰剂组。治疗组患者分剂量服用红霉素14天。反应分为完全缓解、部分缓解或无反应。所有患者随访6周。
两组在就诊时的年龄、性别以及到诊所就诊时的平均病程方面具有可比性。所有患者中有68.8%报告在皮肤病变出现前有上呼吸道感染。治疗组有33例患者（73.33%）达到完全缓解，而安慰剂组无一例完全缓解（P<.0001）。
口服红霉素对玫瑰糠疹患者有效。
